Table 3.
Characteristics of the study population according to their CSF orexin levels (normal levels: NSH/ IH/ NT2 vs low levels in NT1)
| Variable | NSH/ IH/NT2 N = 55 | NT1 N = 39 | |
|---|---|---|---|
| n(%) | n(%) | p | |
| Gender, male | 29 (52.73) | 23 (58.97) | 0.55 |
| Age, years* | 25.00 (12.00; 63.00) | 30.0 (12.2; 55.0) | 0.80 |
| Age, <18 years | 11 (20.00) | 12 (30.77) | 0.23 |
| BMI, kg/m2 * | 22.20 (13.67; 33.20) | 24.22 (17.21; 43.42) | 0.01 |
| Overweight/obese, yes | 5 (9.09) | 8 (20.51) | 0.12 |
| Duration of evolution of sleepiness, years* | 5.22 (0.20; 45.73) | 3.41 (0.02; 37.84) | 0.15 |
| Age of onset of sleepiness, years* | 17.00 (3.00; 48.00) | 20.00 (10.00; 48.00) | 0.07 |
| Drug-naïve, yes | 25 (80.65) | 23 (58.97) | 0.06 |
| ESS score* | 15.50 (0.00; 23.00) | 19.00 (12.00; 24.00) | 0.0002 |
| MSLT, mean latency (min)* | 7.20 (0.80; 19.80) | 2.70 (0.80; 14.67) | <0.0001 |
| MSLT, number of SOREMP* | 1.00 (0.00; 5.00) | 4.00 (2.00; 5.00) | <0.0001 |
| CSF ORX-A levels (pg/mL)* | 308.00 (210.00; 615.00) | 15.0 (0; 97) | NA |
* Continuous variables are expressed as median with minimum value and maximum value.
Abbreviations: BMI, body mass index; CSF, cerebrospinal fluid; ESS, Epworth sleepiness scale; IH, idiopathic hypersomnia; MSLT, mean sleep latency test; NA, test not applicable; NSH, nonspecified hypersomnolence; NT1, narcolepsy type 1; NT2, narcolepsy type 2; ORX-A, orexin-A; SOREMP, sleep onset rapid eye movement period.